Acquisition of subsidiaries and businesses Increase (decrease) through obtaining or losing control of subsidiaries or other businesses, liabilities arising from financing activities Costs of inventories Cost of inventories recognised as expense during period Lease liabilities Lease liabilities [member] Liabilities arising from financing activities [member] Liabilities arising from financing activities [member] BioNTech Europe GmbH BioNTech Europe GmbH [Member] BioNTech Europe GmbH Disclosure of detailed information about property, plant and equipment [line items] Disclosure of detailed information about property, plant and equipment [line items] Non-current obligations under lease contracts Noncurrent Obligations Under Lease Contracts [Member] Noncurrent Obligations Under Lease Contracts Security Exchange Name Security Exchange Name Other provisions Provisions [Member] Provisions Pfizer, Inc Influenza Collaboraiton Pfizer, Inc Influenza Collaboraiton [Member] Pfizer, Inc Influenza Collaboraiton Share of collaboration partners' gross profit and sales milestones COVID-19 Vaccine, Share Of Collaboration Partners' Gross Profit And Sales Milestones [Member] COVID-19 Vaccine, Share Of Collaboration Partners' Gross Profit And Sales Milestones Capital requirements [member] Capital requirements [member] Neon Therapeutics Inc Neon Therapeutics Inc [Member] Neon Therapeutics Inc Goodwill Goodwill Total cash outflow for leases Cash outflow for leases Entity Address, Country Entity Address, Country Maturity [axis] Maturity [axis] BioNTech Diagnostics GmbH BioNTech Diagnostics GmbH [Member] BioNTech Diagnostics GmbH Leases Description of accounting policy for leases [text block] Earnings per share [line items] Earnings per share [line items] Commercial revenues Commercial [Member] Commercial Issuance of share capital and treasury shares Issuance Of Share Capital And Treasury Shares Issuance Of Share Capital And Treasury Shares Attributable to: Profit (loss), attributable to [abstract] 0.8% €1,305,167 loan Zero Point Seven Five Loan [Member] Zero Point Seven Five Loan Depreciation and amortization Accumulated depreciation and amortisation [member] State tax losses State Deferred Tax Assets Operating Loss Carryforwards State Deferred Tax Assets Operating Loss Carryforwards Financial instruments, class [member] Financial instruments, class [member] Trade and other payables Trade and other payables Deferred Expenses Disclosure Of Deferred Expenses Explanatory [Text Block] Disclosure Of Deferred Expenses Explanatory Property, Plant and Equipment Description of accounting policy for property, plant and equipment [text block] Significant Accounting Policies Disclosure of significant accounting policies [text block] Payments related to lease liabilities Payments of lease liabilities, classified as financing activities Production facilities Production Facilities [Member] Production Facilities Property, plant and equipment, Useful life (Years) Useful life measured as period of time, property, plant and equipment Share capital [member] Share capital [member] Loss of acquiree if combination occurred at beginning of period Profit (loss) of combined entity as if combination occurred at beginning of period Share capital Issued capital Change in cash and cash equivalents resulting from exchange rate differences Effect of exchange rate changes on cash and cash equivalents Total current liabilities Current liabilities Financial assets Total financial assets Financial assets Purchase of intangibles assets and right-of-use assets Purchase Of Intangible Assets And Right-Of-Use Assets, Classified As Investing Activities Purchase Of Intangible Assets And Right-Of-Use Assets, Classified As Investing Activities Investment into cash deposit with an original term of six months Purchase Of Cash Deposit With A Term Of More Than Three Months Purchase Of Cash Deposit With A Term Of More Than Three Months Local Phone Number Local Phone Number Liquidity risk Liquidity risk [member] Timing of transfer of goods or services [axis] Timing of transfer of goods or services [axis] Non-deductible expenses Tax effect of expense not deductible in determining taxable profit (tax loss) Loans and borrowings Interest Bearing Loans And Borrowings Interest Bearing Loans And Borrowings 3.5% €50,000,000 bank loan Three Point Five Zero Percentage Secured Bank Loan [Member] Three Point Five Zero Percentage Secured Bank Loan Disclosure of quantitative information about right-of-use assets [line items] Disclosure of quantitative information about right-of-use assets [line items] Provisions non-current and current Provisions NonCurrent And Current Recognised As Of Acquisition Date Provisions NonCurrent And Current Recognised As Of Acquisition Date Entity Listings [Line Items] Entity Listings [Line Items] Federal tax credits Accumulated Tax Losses In Federal Tax Credits Accumulated Tax Losses In Federal Tax Credits Currency [Axis] Currency [Axis] Disclosure of financial liabilities [line items] Disclosure of financial liabilities [line items] Share-based payments (incl. long-term incentive) Key management personnel compensation, share-based payment Expected to be allocated as of estimated allocation date 2024, weighted-average exercise price (in euros per share) Weighted Average Exercise Price Of Share Options Expected To Be Allocated In Share-Based Payment Arrangement, Year Three Weighted Average Exercise Price Of Share Options Expected To Be Allocated In Share-Based Payment Arrangement, Year Three InstaDeep Ltd. Equity investments [member] Goods and services transferred at a point in time Goods or services transferred at point in time [member] Maximum cash payment Maximum Cash Payment In Share-Based Payment Arrangement Maximum Cash Payment In Share-Based Payment Arrangement Other liabilities non-current and current Other Current And Non-Current Liabilities Recognised As Of Acquisition Date Other Current And Non-Current Liabilities Recognised As Of Acquisition Date Germany GERMANY Categories of financial assets [axis] Categories of financial assets [axis] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Intangible assets Identifiable intangible assets recognised as of acquisition date Sean Marett Sean Marett [Member] Sean Marett Other performance-related variable compensation Key Management Personnel Compensation, Other Performance-Related Variable Compensation Key Management Personnel Compensation, Other Performance-Related Variable Compensation Other Financial Liabilities Other Financial Liabilities [Member] Other Financial Liabilities No Trading Symbol Flag No Trading Symbol Flag Contingent consideration Contingent liabilities recognised in business combination Concessions, licenses, in-process R&D and similar rights Concessions, Licenses, In-Process Research And Development And Similar Rights [Member] Concessions, Licenses, In-Process Research And Development And Similar Rights Treasury shares Treasury shares [member] Sales and marketing expenses Sales And Marketing Expense [Member] Sales And Marketing Expense Entity's total for consolidated structured entities [member] Entity's total for consolidated structured entities [member] Interest expenses related to lease liabilities Interest on lease liabilities Interest expense on lease liabilities Classes of liabilities [axis] Classes of liabilities [axis] Research and Development Expenses Disclosure Of Research And Development Expenses Explanatory [Table Text Block] Disclosure Of Research And Development Expenses Explanatory Goods and services transferred over time Goods or services transferred over time [member] Buildings Buildings [member] Discovery collaboration term Collaboration Agreement, Term Collaboration Agreement, Term Secured bank loan Financial assets pledged as collateral for liabilities or contingent liabilities Other Provisions, Contingent Liabilities And Contingent Assets [Abstract] Other Provisions, Contingent Liabilities And Contingent Assets [Abstract] Deferred remuneration Deferred Remuneration From Business Combination Deferred Remuneration From Business Combination Borrowings by name [member] Borrowings by name [member] Proceeds from sale of property, plant and equipment Proceeds from sales of property, plant and equipment, classified as investing activities Line items by function [member] Line items by function [member] BioNTech RNA Pharmaceuticals GmbH BioNTech RNA Pharmaceuticals GmbH [Member] BioNTech RNA Pharmaceuticals GmbH Entity Voluntary Filers Entity Voluntary Filers Belgium BELGIUM Allocated under LTI 2021 program Number Of Instruments Other Equity Instruments Allocated Number Of Instruments Other Equity Instruments Allocated Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Purchased services Purchased Services [Member] Purchased Services Deutsche Bank AG Deutsche Bank AG [Member] Deutsche Bank AG Phantom shares awarded (in shares) Key Management Personnel Compensation, Phantom Shares Awarded Key Management Personnel Compensation, Phantom Shares Awarded Provisions Current provisions List Of Accounting Policies [Abstract] List Of Accounting Policies [Abstract] List Of Accounting Policies [Abstract] Proceeds from loans and borrowings Proceeds from borrowings, classified as financing activities Total compensation paid to key management personnel Key management personnel compensation Options outstanding, weighted-average expected life Weighted average remaining contractual life of outstanding share options Wages and salaries Wages and salaries Total Employee benefits expense reSano GmbH reSano GmbH [Member] reSano GmbH Basis of Consolidation Disclosure of basis of consolidation [text block] Scenario [Axis] Scenario [Axis] Disclosure of temporary difference, unused tax losses and unused tax credits [table] Disclosure of temporary difference, unused tax losses and unused tax credits [table] Total Other liabilities Disclosure of reserves within equity [line items] Disclosure of reserves within equity [line items] Total Equity attributable to owners of parent [member] Vesting percentage after one year Vesting Percentage Of Share Based Payment Arrangement Vesting Percentage Of Share Based Payment Arrangement Equity holders of the parent Comprehensive income, attributable to owners of parent Non tax-effective share-based payment expenses Non-Recognition Of Tax Effect On Share-Based Payment Expenses Non-Recognition Of Tax Effect On Share-Based Payment Expenses Entity Interactive Data Current Entity Interactive Data Current Acquisition of subsidiaries and businesses Increase (decrease) through business combinations, deferred tax liability (asset) % equity interest Ownership of ordinary shares in BioNTech (in %) Proportion of ownership interest in subsidiary Issuance of treasury shares Issueance of share capital Issue of equity Contingent consideration liability Contingent consideration recognised as of acquisition date Number of secured bank loans Number Of Secured Bank Loan Maintained Number Of Secured Bank Loan Maintained Property, plant and equipment [member] Property, plant and equipment [member] Ordinary shares issued price per share (in euros per share) Shares Issued Price Per Share 1 Shares Issued Price Per Share 1 -0.05 Negative Five Percentage Change In Foreign Exchange Rate [Member] Negative Five Percentage Change In Foreign Exchange Rate Average rate Average foreign exchange rate Employee Benefits Expense Disclosure Of Detailed Information About Employee Benefits Expense Explanatory [Table Text Block] Disclosure Of Detailed Information About Employee Benefits Expense Explanatory Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Goodwill Goodwill [member] Other Liabilities Disclosure of other liabilities [text block] Profit / (loss) before tax Profit / (loss) before tax Profit (loss) before tax Cash And Cash Equivalents [Table] Cash And Cash Equivalents [Table] Cash And Cash Equivalents [Table] Financial Instruments - Initial Recognition and Subsequent Measurement Description of accounting policy for financial instruments [text block] Sales tax receivable Receivables from taxes other than income tax Expected to be allocated as of estimated allocation date 2023, weighted-average exercise price (in euros per share) Weighted Average Exercise Price Of Share Options Expected To Be Allocated In Share-Based Payment Arrangement, Year Two Weighted Average Exercise Price Of Share Options Expected To Be Allocated In Share-Based Payment Arrangement, Year Two Disclosure of detailed information about business combination [line items] Disclosure of detailed information about business combination [line items] Reclassifications Reclassifications Of Property, Plant And Equipment Reclassifications Of Property, Plant And Equipment Option to purchase ordinary shares (in shares) Number of instruments granted in share-based payment arrangement Finance expenses Finance expenses Finance costs Trade and other receivables Trade and other current receivables Increase in inventories Adjustments for decrease (increase) in inventories Loss on derivative instruments at fair value through profit or loss Loss On Derivative Instruments At Fair Value [Member] Loss On Derivative Instruments At Fair Value Disclosure of reserves within equity [table] Disclosure of reserves within equity [table] Percentage of ADS to ordinary shares Percentage Of American Depository Shares To Ordinary Shares Percentage Of American Depository Shares To Ordinary Shares Deferred tax liabilities recognized Deferred tax liabilities recognised as of acquisition date Disclosure of financial liabilities [table] Disclosure of financial liabilities [table] Document Transition Report Document Transition Report Deferred expenses from CRO and CMO contracts Deferred Expenses From Contract Manufacturing And Contract Research Organizations Deferred Expenses From Contract Manufacturing And Contract Research Organizations Maximum gross proceeds receivable form issuance of ordinary shares Maximum Proceeds Receivable From Issuance Of Ordinary Shares Maximum Proceeds Receivable From Issuance Of Ordinary Shares Deferred Expenses [Abstract] Deferred Expenses [Abstract] Earnings per Share Disclosure of earnings per share [text block] Summary of Fair Values of Identifiable Net Assets Disclosure of detailed information about business combination [text block] Share of collaboration partners' sales milestones COVID-19 Vaccine, Share Of Collaboration Partners' Sales Milestones [Member] COVID-19 Vaccine, Share Of Collaboration Partners' Sales Milestones June 2020 Private Placement June Twenty Twenty Private Placement [Member] June Twenty Twenty Private Placement BioNTech USA Holding, LLC BioNTech USA Holding, LLC [Member] BioNTech USA Holding, LLC ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag JPT Peptide Technologies Inc. JPT Peptide Technologies Inc. [Member] JPT Peptide Technologies Inc. Interest paid Interest paid, classified as operating activities American depositary shares (in shares) American Depositary Shares American Depositary Shares Ownership [Axis] Ownership [Axis] Legal Entity [Axis] Legal Entity [Axis] Pfizer, Inc COVID-19 Vaccine Collaboration Pfizer, Inc COVID-19 Vaccine Collaboration [Member] Pfizer, Inc COVID-19 Vaccine Collaboration Major customers [axis] Major customers [axis] Document Shell Company Report Document Shell Company Report Statement of changes in equity [abstract] Disclosure Of Income And Expenses [Table] Disclosure Of Income And Expenses [Table] Disclosure Of Income And Expenses Summary of Income and Share Data Used in the Basic and Diluted EPS Calculations Earnings per share [text block] Other operating income Miscellaneous other operating income Total current assets Current assets Other liabilities Total non-current Other non-current liabilities Financial liabilities at fair value through profit or loss Financial liabilities at fair value through profit or loss Summary of Goodwill Recognized Disclosure Of Goodwill Acquired In Respective Business Combinations Explanatory [Table Text Block] Disclosure Of Goodwill Acquired In Respective Business Combinations Explanatory Disclosure of other provisions [line items] Disclosure of other provisions [line items] Disclosure of detailed information about intangible assets [line items] Disclosure of detailed information about intangible assets [line items] Construction in progress and advance payments Construction In Progress And Advance Payments [Member] Construction In Progress And Advance Payments Entity [Domain] Entity [Domain] Additions to right-of-use assets Additions to right-of-use assets Other comprehensive income / (loss) that may be reclassified to profit or loss in subsequent periods, net of tax Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract] Weighted average fair value Weighted average fair value at measurement date, share options granted Pension costs Post-employment benefit expense in profit or loss, defined benefit plans Exercise price in translation for IPO Exercise Price Currency Translation Of Public Offering Price Per Share Exercise Price Currency Translation Of Public Offering Price Per Share Other Other Deferred Expenses Other Deferred Expenses Depreciation and amortization of property, plant, equipment, intangible assets and right-of-use assets Adjustments for depreciation and amortisation expense Property, plant and equipment Property, plant and equipment recognised as of acquisition date Diluted profit/(loss) for the period per share (in euros per share) Diluted earnings (loss) per share Deferred taxes Deferred tax expense (income) Granted under LTI 2020 and LTI-plus program (in shares) Number of other equity instruments granted in share-based payment arrangement Document Fiscal Year Focus Document Fiscal Year Focus Group Information Disclosure of composition of group [text block] Total Expense from share-based payment transactions with employees Refund liabilities Refunds provision Right-of-use assets Right-of-use assets [member] Loans and borrowings Non-current portion of non-current borrowings Total non-current Non-current financial liabilities at amortised cost Revenues derived from deferred upfront payments Revenues Derived From Deferred Upfront Payments Revenues Derived From Deferred Upfront Payments Entity's total for business combinations [member] Entity's total for business combinations [member] Other Assets Disclosure of other assets [text block] Change in valuation allowance Tax Effect Of Change In Valuation Allowance Tax Effect Of Change In Valuation Allowance Foreign exchange gain Foreign exchange differences, net Net foreign exchange gain Impairment of Non-Financial Assets Description of accounting policy for impairment of non-financial assets [text block] Maximum Maximum [Member] Unsatisfied Or Partially Unsatisfied Unsatisfied Or Partially Unsatisfied [Member] Unsatisfied Or Partially Unsatisfied Address Type [Domain] Address Type [Domain] Disclosure of performance obligations [line items] Disclosure of performance obligations [line items] Shares issued during period, stock split (in shares) Shares Issued During Period, Stock Split Shares Issued During Period, Stock Split Threshold amount of dividend by number of shares outstanding immediately following initial public offering Threshold Amount Of Dividend By Number Of Shares Outstanding Immediately Following Initial Public Offering Threshold Amount Of Dividend By Number Of Shares Outstanding Immediately Following Initial Public Offering Financial assets at fair value through other comprehensive income Financial assets at fair value through other comprehensive income, category [member] Property, plant and equipment [abstract] City Area Code City Area Code Beginning balance, number of ordinary shares underlying options (in shares) Ending balance, number of ordinary shares underlying options (in shares) Number of ordinary shares underlying options (in shares) Number Of Ordinary Shares Underlying Options Outstanding Number Of Ordinary Shares Underlying Options Outstanding Earnings per share Basic earnings per share [abstract] Other assets non-current and current Other Noncurrent and Current Assets Recognised As Of Acquisition Date Other Noncurrent and Current Assets Recognised As Of Acquisition Date Amortization of financial instruments Amortization Of Financial Instruments Amortization Of Financial Instruments TRON TRON [Member] TRON Other Other Sales And Marketing Expense [Member] Other Sales And Marketing Expense Disclosure of transactions between related parties [table] Disclosure of transactions between related parties [table] Expected to be allocated as of estimated allocation date 2023, share options (in shares) Number Of Share Options Expected To Be Allocated In Share-Based Payment Arrangement, Year Two Number Of Share Options Expected To Be Allocated In Share-Based Payment Arrangement, Year Two Stock split ratio Stock Split Conversion Ratio Stock Split Conversion Ratio State tax credits Accumulated Tax Losses In State Tax Credits Accumulated Tax Losses In State Tax Credits Percentage of target share price applicable for prior twelve month period Percentage Of Target Share Price Applicable For Prior Twelve Month Percentage Of Target Share Price Applicable For Prior Twelve Month Changes Regarding Government Grants Disclosure Of Changes Regarding Government Grants Explanatory [Table Text Block] Disclosure Of Changes Regarding Government Grants Explanatory Liabilities Liabilities [abstract] BioNTech Real Estate An der Goldgrube GmbH & Co. KG BioNTech Real Estate An der Goldgrube GmbH & Co. KG [Member] BioNTech Real Estate An der Goldgrube GmbH & Co. KG Adjustments to reconcile profit / (loss) before tax to net cash flows: Adjustments to reconcile profit (loss) [abstract] Classes of financial instruments [axis] Classes of financial instruments [axis] Prepayments related to service contracts Current Prepayments Related To Service Contracts Current Prepayments Related To Service Contracts Inventories Description of accounting policy for measuring inventories [text block] BioNTech Real Estate Verwaltungs GmbH BioNTech Real Estate Verwaltungs GmbH [Member] BioNTech Real Estate Verwaltungs GmbH Cash and cash equivalents Cash and cash equivalents recognised as of acquisition date Hedging instruments [member] Hedging instruments [member] Advance payments Advance Payments [Member] Advance Payments Entity Registrant Name Entity Registrant Name Employee Equity Plan Employee Equity Plan [Member] Employee Equity Plan Cash and Cash Equivalents Description of accounting policy for determining components of cash and cash equivalents [text block] Disclosure Of Corporate Information Explanatory [Abstract] Disclosure Of Corporate Information Explanatory [Abstract] Disclosure Of Corporate Information Explanatory [Abstract] Global Offering Global Offering [Member] Global Offering Summary of Reconciliation of Expected Income Tax Benefit to Actual Income Tax Benefit Disclosure Of Reconciliation Of Expected Income Tax Benefit To Actual Income Tax Benefit Explanatory [Table Text Block] Disclosure Of Reconciliation Of Expected Income Tax Benefit To Actual Income Tax Benefit Explanatory Timing of transfer of goods or services [member] Timing of transfer of goods or services [member] Currency risk Currency risk [member] Cost of sales Cost of sales [member] Allocated under LTI 2021 program (in euros per share) Weighted Average Exercise Price Of Other Equity Instruments Allocated In Share-based Payment Arrangement Weighted Average Exercise Price Of Other Equity Instruments Allocated In Share-based Payment Arrangement June 2020 Private Placement June 2020 Private Placement [Member] June 2020 Private Placement Document Fiscal Period Focus Document Fiscal Period Focus Business Combinations and Goodwill Description of accounting policy for business combinations and goodwill [text block] Expected to be allocated as of estimated allocation date 2026, weighted-average exercise price (in euros per share) Weighted Average Exercise Price Of Share Options Expected To Be Allocated In Share-Based Payment Arrangement, Year Five Weighted Average Exercise Price Of Share Options Expected To Be Allocated In Share-Based Payment Arrangement, Year Five Beginning balance Ending balance Liabilities arising from financing activities Total non-current Non-current financial liabilities Summary of Cash and Cash Equivalents Disclosure Of Cash And Cash Equivalents Explanatory [Table Text Block] Disclosure Of Cash And Cash Equivalents Explanatory Deferred tax assets and liabilities, net recognized Deferred Tax Assets Net Deferred Tax Assets Net Deferred tax liability (asset) Interest rate Borrowings, interest rate Summary of Revenue Recognized Disclosure Of Recognition Of Revenue Explanatory [Table Text Block] Disclosure Of Recognition Of Revenue Explanatory Number of neoantigen targeted therapies under development Intangible Assets Number Of Neoantigen Targeted Therapies Under Development Intangible Assets Number Of Neoantigen Targeted Therapies Under Development Depreciation Depreciation, property, plant and equipment Reclassification Increase Decrease Through Reclassification, Liabilities Arising From Financing Activities Increase Decrease Through Reclassification, Liabilities Arising From Financing Activities Contract liabilities Non-current contract liabilities Contract liabilities Contract Liabilities [Member] Contract Liabilities Federal tax losses subject to expiration Federal Deferred Tax Assets Operating Loss Carryforwards Expected To Expire Federal Deferred Tax Assets Operating Loss Carryforwards Expected To Expire COVID-19 vaccine revenues COVID-19 Vaccine Revenues [Member] COVID-19 Vaccine Revenues Short-term incentive - second installment Key management personnel compensation, short-term employee benefits Summary of Information about Entity with Significant Influence Over Group Disclosure Of Entity With Significant Influence Over Group Explanatory [Table Text Block] Disclosure Of Entity With Significant Influence Over Group Explanatory Sales and marketing expenses Sales and marketing expenses Sales and marketing expense Sales milestone receivable Collaboration Agreement, Sales Milestone Receivable Collaboration Agreement, Sales Milestone Receivable One time signing bonus Key Management Personnel Compensation, One-Time Signing bonus Key Management Personnel Compensation, One-Time Signing bonus Current obligations under lease contracts Current Obligations Under Lease Contracts [Member] Current Obligations Under Lease Contracts Statement of comprehensive income [abstract] Refund liabilities Current refunds provision Disclosure of subsidiaries [table] Disclosure of subsidiaries [table] U.S. dollar Bank accounts US Dollar Bank Accounts [Member] US Dollar Bank Accounts Net employee defined benefit liabilities Net defined benefit liability (asset) [member] Bargain purchase Bargain Purchase [Member] Bargain Purchase Genentech Inc. Genentech Inc [Member] Genentech Inc Counterparty Name [Domain] Counterparty Name [Domain] Other Other [Member] Other Document Registration Statement Document Registration Statement Retained earnings / (accumulated losses) Accumulated other comprehensive income [member] Income tax liabilities Current tax liabilities, current Financial assets, class [member] Financial assets, class [member] BioNTech Research and Development, Inc. BioNTech Research And Development, Inc. [Member] BioNTech Research And Development, Inc. Classes of financial liabilities [axis] Classes of financial liabilities [axis] Revenues from Contracts with Customers Disclosure of revenue from contracts with customers [text block] Auditor Location Auditor Location BioNTech Innovation GmbH (in establishment) BioNTech Innovation GmbH [Member] BioNTech Innovation GmbH Fixed assets Fixed Assets [Member] Fixed Assets Expense arising from cash-settled share-based payment arrangements Expense from cash-settled share-based payment transactions Adjustments for decrease in trade and other receivables Adjustments for decrease (increase) in trade and other receivables Summary of Deferred Expenses Disclosure Of Deferred Expenses Explanatory [Table Text Block] Disclosure Of Deferred Expenses Explanatory Disclosure of disaggregation of revenue from contracts with customers [line items] Disclosure of disaggregation of revenue from contracts with customers [line items] Cash paid Cash paid (included in cash flow used in investing activities) Cash transferred Summary of Deferred Taxes Disclosure of temporary difference, unused tax losses and unused tax credits [text block] Total equity Equity at beginning of period Equity at end of period Equity Summary of Other Liabilities Disclosure Of Detailed Information About Other Liabilities Explanatory [Table Text Block] Disclosure Of Detailed Information About Other Liabilities Explanatory Title of 12(b) Security Title of 12(b) Security Disclosure of disaggregation of revenue from contracts with customers [table] Disclosure of disaggregation of revenue from contracts with customers [table] BioNTech R&D (Austria) GmbH (previously PhagoMed Biopharma GmbH) BioNTech R&D (Austria) GmbH (previously PhagoMed Biopharma GmbH) [Member] BioNTech R&D (Austria) GmbH (previously PhagoMed Biopharma GmbH) IT and office equipment Office equipment [member] Bargain purchase Bargain purchase Gain recognised in bargain purchase transaction Title of Individual [Axis] Title of Individual [Axis] +5 % Positive Five Percentage Change In Foreign Exchange Rate [Member] Positive Five Percentage Change In Foreign Exchange Rate AT Impf GmbH AT Impf GmbH [Member] AT Impf GmbH Document Type Document Type Tax-free income Tax effect of revenues exempt from taxation Product and Service [Domain] Product and Service [Domain] External Product Sales of JPT External Product Sales To JPT [Member] External Product Sales To JPT Basis of Preparation Statement of IFRS compliance [text block] Business Contact Business Contact [Member] Upfront consideration less acquired debt Consideration Transferred, Net Of Liabilities Incurred Consideration Transferred, Net Of Liabilities Incurred Net cash flow on acquisition Net Cash Flow Of Business Combination Net Cash Flow Of Business Combination Granted under LTI 2020 and LTI-plus program (in euros per share) Weighted average exercise price of other equity instruments granted in share-based payment arrangement Total Total trade payables and other financial liabilities at amortized cost, other than loans and borrowings Financial liabilities at amortised cost Government Grants Description of accounting policy for government grants [text block] Types of risks [axis] Types of risks [axis] Other non-cash income Other adjustments for non-cash items Fixed compensation Key Management Personnel Compensation, Fixed Compensation Key Management Personnel Compensation, Fixed Compensation Disclosure of terms and conditions of share-based payment arrangement [line items] Disclosure of terms and conditions of share-based payment arrangement [line items] Contact Personnel Email Address Contact Personnel Email Address Geographical [Axis] Geographical [Axis] BioNTech Real Estate Adam Opel Straße GmbH & Co. KG BioNTech Real Estate Adam Opel Straße GmbH & Co. KG [Member] BioNTech Real Estate Adam Opel Straße GmbH & Co. KG Non-current assets Non-current assets [abstract] Foreign exchange differences, net Foreign Exchange Differences [Member] Foreign Exchange Differences Estimated milestone payment to be received Estimated Milestone Payment To Be Received At Contract Inception Estimated Milestone Payment To Be Received At Contract Inception Equity and liabilities Equity and liabilities [abstract] Disclosure of other provisions [table] Disclosure of other provisions [table] BioNTech (Shanghai) Pharmaceuticals Co. Ltd. BioNTech (Shanghai) Pharmaceuticals Co. Ltd. [Member] BioNTech (Shanghai) Pharmaceuticals Co. Ltd. Net foreign exchange differences Adjustments for unrealised foreign exchange losses (gains) Other Other Current Assets, Other Other Current Assets, Other At-The-Market Offering Program At Market Offering Program [Member] At Market Offering Program Equity holders of the parent Profit / (loss) attributable to ordinary equity holders of the parent for basic earnings Profit (loss), attributable to owners of parent Proceeds from issuance of share capital and treasury shares, net of costs Proceeds from issuing shares Operating activities Cash flows from (used in) operating activities [abstract] Classes of property, plant and equipment [axis] Classes of property, plant and equipment [axis] Reclassification for share-based payment arrangement Reclassification Of Share-Based Payment Arrangement Reclassification Of Share-Based Payment Arrangement Disposals Disposals, intangible assets and goodwill BioNTech Real Estate Holding GmbH BioNTech Real Estate Holding GmbH [Member] BioNTech Real Estate Holding GmbH Total current Current financial liabilities at amortised cost LTI-plus Program Employee Equity Plan, Long-Term Incentive Plus Program [Member] Employee Equity Plan, Long-Term Incentive Plus Program Total current Current financial assets Trade and other receivables Current trade receivables Revenue from Contracts with Customers Description of accounting policy for recognition of revenue [text block] Summary of Compensation of Key Management Personnel Disclosure of information about key management personnel [text block] Lease liabilities Lease liabilities Lease liabilities Assets [member] Assets [member] Non-controlling interest Non-controlling interests [member] Disclosure of financial assets [table] Disclosure of financial assets [table] Share-Based Payments Description of accounting policy for share-based payment transactions [text block] Other Other Income Expense [Member] Other Income Expense Renumeration payment Remuneration Payment Remuneration Payment Other effects Other tax effects for reconciliation between accounting profit and tax expense (income) Other financial liabilities Other non-current financial liabilities Net cash flows from / (used in) operating activities Cash flows from (used in) operating activities Other reserves Other reserves [member] Statutory tax rate Applicable tax rate Intangible Assets [Abstract] Intangible Assets [Abstract] Intangible Assets [Abstract] Document Period End Date Document Period End Date Social security costs Social security contributions BioNTech Real Estate GmbH & Co. KG BioNTech Real Estate GmbH & Co. KG [Member] BioNTech Real Estate GmbH & Co. KG Goodwill from the acquisition Goodwill recognised as of acquisition date Statement of changes in equity [table] Statement of changes in equity [table] Contract liabilities Current contract liabilities Disclosure of detailed information about intangible assets [table] Disclosure of detailed information about intangible assets [table] CGU Immunotherapies CGU Immunotherapies [Member] CGU Immunotherapies German Federal Ministry of Health German Federal Ministry of Health [Member] German Federal Ministry of Health Disclosure of reconciliation of changes in intangible assets and goodwill [line items] Disclosure of reconciliation of changes in intangible assets and goodwill [line items] Treasury shares Treasury shares More than one year Later than one year [member] Aggregate value of merger consideration Consideration Transferred Consideration Transferred Trade payables Trade and other current payables Gross carrying amount Gross carrying amount [member] Events After the Reporting Period Disclosure of events after reporting period [text block] Currency differences Increase (decrease) through net exchange differences, intangible assets and goodwill 1.9% €3,528,892 secured bank loan One Point Nine Zero Percentage Secured Bank Loan [Member] One Point Nine Zero Percentage Secured Bank Loan Disclosure of non-adjusting events after reporting period [line items] Disclosure of non-adjusting events after reporting period [line items] Trade and other receivables Trade receivables [member] Summary of Amounts Recognized in Consolidated Statement of Operations Disclosure Of Detailed Information About Lease Expense Recognized In Statement Of Operations Explanatory [Table Text Block] Disclosure Of Detailed Information About Lease Expense Recognized In Statement Of Operations Explanatory Earnings per share Earnings per share [abstract] Other financial liabilities Other current financial liabilities Total equity and liabilities Equity and liabilities Summary of Financial Assets at Amortized Cost and at Fair Value through Profit or Loss Disclosure of financial assets [text block] Tax rate for deferred taxes Tax Rate On Deferred Taxes Tax Rate On Deferred Taxes Standard Issued but Not Yet Effective Description Of Accounting Policy For Standards Issued But Not Yet Effective Explanatory [Policy Text Block] Description Of Accounting Policy For Standards Issued But Not Yet Effective Explanatory Total non-current Non-current financial assets Inventories Disclosure of inventories [text block] Entity Current Reporting Status Entity Current Reporting Status Corporate tax Accumulated Tax Losses In Corporate Tax Accumulated Tax Losses In Corporate Tax Document Accounting Standard Document Accounting Standard Maximum Top of range [member] Net cash flows used in investing activities Cash flows from (used in) investing activities Expense related to short-term leases (included in other expenses) Expense relating to short-term leases for which recognition exemption has been used Announcement Of Research, Development And Commercialization Collaboration Agreement Announcement Of Research, Development And Commercialization Collaboration Agreement [Member] Announcement Of Research, Development And Commercialization Collaboration Agreement Schedule of Standards Issued but Not Yet Effective Disclosure of expected impact of initial application of new standards or interpretations [text block] Counterparty Name [Axis] Counterparty Name [Axis] United States United States UNITED STATES Announcement Of Multi-Target Research Collaboration Agreement Announcement Of Multi-Target Research Collaboration Agreement [Member] Announcement Of Multi-Target Research Collaboration Agreement Loans and borrowings Interest Bearing Loans And Borrowings [Member] Interest Bearing Loans And Borrowings Borrowings by name [axis] Borrowings by name [axis] Income tax received / (paid), net Income taxes paid (refund), classified as operating activities Current provisions for international trade obligations Current Provisions For International Trade Obligations Current Provisions For International Trade Obligations (Decrease) / Increase in trade payables, other financial liabilities, other liabilities, contract liabilities, refund liabilities and provisions Adjustments For Increase (Decrease) In Trade Payables, Other Liabilities, Contract Liabilities And Provisions Adjustments For Increase (Decrease) In Trade Payables, Other Liabilities, Contract Liabilities And Provisions Net other comprehensive income / (loss) that may be reclassified to profit or loss in subsequent periods Other comprehensive income that will be reclassified to profit or loss, net of tax Entity Address, Postal Zip Code Entity Address, Postal Zip Code Property, Plant and Equipment Disclosure of property, plant and equipment [text block] Granted, share options (in shares) Granted shares (in shares) Number of share options granted in share-based payment arrangement Raw materials and supplies Current raw materials and current production supplies Total liabilities Liabilities Derivatives not designated as hedging instrument Derivative Financial Liabilities Not Designated As Hedging Instruments At Fair Value Derivative Financial Liabilities Not Designated As Hedging Instruments At Fair Value Key Management Personnel of Entity or Parent Key management personnel of entity or parent [member] Aggregate proceeds from issuance of ordinary share Proceeds from issue of ordinary shares Income Tax Disclosure of income tax [text block] Entity Address, Address Line One Entity Address, Address Line One Attribution of expenses by nature to their function [axis] Attribution of expenses by nature to their function [axis] Entity Shell Company Entity Shell Company Released to the consolidated statements of profit or loss Released to the consolidated statements of profit or loss Income from government grants Schedule of proposed cash dividend distributions Disclosure Of Proposed Cash Dividend Distributions [Table Text Block] Disclosure Of Proposed Cash Dividend Distributions Finance income Adjustments for finance income Valuation adjustment Valuation Adjustment [Member] Valuation Adjustment Other related parties Other related parties [member] Useful Lives Applied to the Group's Intangible Assets Disclosure of detailed information about intangible assets [text block] Current Fiscal Year End Date Current Fiscal Year End Date Leases [Abstract] Leases [Abstract] Leases [Abstract] Contract liabilities Contract liabilities Subsidiaries Subsidiaries [member] Price of ADS as a percentage of exercise price, maximum Price Of American Depository Share As A Percentage Of Exercise Price, Maximum Price Of American Depository Share As A Percentage Of Exercise Price, Maximum Tax losses / tax credits Unused tax credits [member] Total non-current assets Total non-current assets Non-current assets Forfeited, share options (in shares) Number of share options forfeited in share-based payment arrangement Forfeited, weighted-average exercise price (in euros per share) Weighted average exercise price of share options forfeited in share-based payment arrangement Consolidated structured entities [axis] Consolidated structured entities [axis] Exchange differences on translation of foreign operations Other comprehensive income, net of tax, exchange differences on translation of foreign operations Profit or loss [abstract] Working capital adjustments: Working Capital Adjustments [Abstract] Working Capital Adjustments Minimum Bottom of range [member] Effects of dilution from share options (in shares) Dilutive effect of share options on number of ordinary shares General and Administrative Expenses Disclosure Of General And Administrative Expenses Explanatory [Table Text Block] Disclosure Of General And Administrative Expenses Explanatory Total current Current financial liabilities Statistical Measurement [Axis] Statistical Measurement [Axis] Other sales Other Sales [Member] Other Sales BioNTech Austria Beteiligungen GmbH BioNTech Austria Beteiligungen GmbH [Member] BioNTech Austria Beteiligungen GmbH Summary of Financial Liabilities at Amortized Cost Disclosure of financial liabilities [text block] Additions Additions other than through business combinations, intangible assets other than goodwill Financial liabilities, class [member] Financial liabilities, class [member] Non refundable upfront cash payment Non-Refundable Upfront Cash Payment Non-Refundable Upfront Cash Payment Deferred tax liabilities Deferred tax liabilities U.S. dollar United States of America, Dollars Scenario [Domain] Scenario [Domain] Share-Based Payments Disclosure of share-based payment arrangements [text block] Option rights exercisable period Option Exercisable Period Option Exercisable Period Entity Listings [Table] Entity Listings [Table] Prepayments related to CRO and CMO contracts Current advances to suppliers Other Increase (decrease) through other changes, liabilities arising from financing activities Equity [member] Equity [member] BioNTech Manufacturing GmbH BioNTech Manufacturing GmbH [Member] BioNTech Manufacturing GmbH Range [axis] Range [axis] Liabilities [member] Liabilities [member] Business Combinations [Abstract] Business Combinations [Abstract] Business Combinations [Abstract] Cofounder And Chief Executive Officer Cofounder And Chief Executive Officer [Member] Cofounder And Chief Executive Officer Remeasurement income / (loss) on defined benefit plans Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans Subsidiaries [axis] Subsidiaries [axis] Disclosure of detailed information about property, plant and equipment [table] Disclosure of detailed information about property, plant and equipment [table] Intangible assets and goodwill [member] Intangible assets and goodwill [member] Liabilities arising from financing activities [axis] Liabilities arising from financing activities [axis] Royalty fee adjustment as a percentage of revenue Royalty Fee Adjustment As A Percentage Of Revenue Royalty Fee Adjustment As A Percentage Of Revenue Assets Assets [abstract] Statistical Measurement [Domain] Statistical Measurement [Domain] Entity Addresses, Address Type [Axis] Entity Addresses, Address Type [Axis] Schedule of Number and Share Price of Restricted Stock Units Disclosure of number and weighted average exercise prices of other equity instruments [text block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Customers [member] Customers [member] Convertible Note Convertible Note [Member] Convertible Note Loss since acquisition date Profit (loss) of acquiree since acquisition date Contact Personnel Name Contact Personnel Name Research and development expenses Research And Development Expenses [Member] Research And Development Expenses Summary of Contract Liabilities Allocated to Remaining Performance Obligations (Unsatisfied or Partially Unsatisfied) Disclosure of performance obligations [text block] Risk-free interest rate (%) Risk free interest rate, share options granted Ordinary shares, no par value, with a notional amount attributable to each ordinary share of €1 Ordinary Shares, No Par Value, With National Amount Attributable To Each Ordinary Share [Member] Ordinary Shares, No Par Value, With National Amount Attributable To Each Ordinary Share Equity issuable Equity Issuable Equity Issuable Total Other assets Entity File Number Entity File Number Payment terms in contracts with customers Description of significant payment terms in contracts with customers Cash Interest Fixed Rate Cash Interest Fixed Rate [Member] Cash Interest Fixed Rate Financial Assets and Financial Liabilities Disclosure of offsetting of financial assets and financial liabilities [text block] Additions Additions other than through business combinations, property, plant and equipment Management Board Management Board [Member] Management Board Short-term incentive compensation Share-Based Payment Arrangement, Short-Term Incentive Compensation Share-Based Payment Arrangement, Short-Term Incentive Compensation Trade tax Accumulated Tax Losses In Trade Tax Accumulated Tax Losses In Trade Tax Closing rate Closing foreign exchange rate One year Share-Based Payment Arrangement, Year One [Member] Share-Based Payment Arrangement, Year One Deferred expenses Total current Deferred Expense Current Deferred Expense Current Shanghai Fosun Pharmaceutical (Group) Co., Ltd Shanghai Fosun Pharmaceutical (Group) Co., Ltd [Member] Shanghai Fosun Pharmaceutical (Group) Co., Ltd Medine GmbH Medine GmbH [Member] Medine GmbH Number of fixed-interest rate loans Number Of Fixed-Interest Rate Loans Number Of Fixed-Interest Rate Loans Expected to be allocated as of estimated allocation date 2025, share options (in shares) Number Of Share Options Expected To Be Allocated In Share-Based Payment Arrangement, Year Four Number Of Share Options Expected To Be Allocated In Share-Based Payment Arrangement, Year Four Weighted average share price (in euros per share) Weighted average share price, share options granted Useful Lives Applied to the Group's Property, Plant and Equipment Summary of Property, Plant and Equipment Disclosure of detailed information about property, plant and equipment [text block] Classes of intangible assets other than goodwill [axis] Classes of intangible assets other than goodwill [axis] Short-term incentive - second installment Key Management Personnel Compensation, Short-Term Employee Benefits, Second Installment Key Management Personnel Compensation, Short-Term Employee Benefits, Second Installment Summary of Detailed Information About Intangible Assets Disclosure of reconciliation of changes in intangible assets and goodwill [text block] Vesting [Axis] Vesting [Axis] Vesting Title of Individual [Domain] Title of Individual [Domain] Currency differences Increase (decrease) through net exchange differences, property, plant and equipment Estimated allocation date 2023 Estimated Allocation Date Two [Member] Estimated Allocation Date Two Expected volatility (%) Expected volatility, share options granted More than 5 years Later than five years [member] Inventories Inventory [Member] Inventory Sales to collaboration partners COVID-19 Vaccine, Sales To Collaboration Partners [Member] COVID-19 Vaccine, Sales To Collaboration Partners Other liabilities Total current Other current liabilities Effective interest rate Effective Interest Rate Of Financial Liabilities Effective Interest Rate Of Financial Liabilities Prof. Ugur Sahin, M.D. Professor Ugur Sahin MD [Member] Professor Ugur Sahin MD Contingent consideration Contingent consideration [member] Investments in equity instruments designated at fair value through other comprehensive income [axis] Investments in equity instruments designated at fair value through other comprehensive income [axis] Provisions Description of accounting policy for provisions [text block] Classes of assets [axis] Classes of assets [axis] Acquisition of subsidiaries and businesses Acquisitions through business combinations, property, plant and equipment Non-controlling interests Profit (loss), attributable to non-controlling interests Amounts included in contract liabilities at the beginning of the year Revenue that was included in contract liability balance at beginning of period Maturity period Financial Liability Maturity Term Financial Liability Maturity Term Government grants Government Grants [Member] Government Grants Share of colaborations partners' gross profit COVID-19 Vaccine, Share Of Collaboration Partners' Gross Profit [Member] COVID-19 Vaccine, Share Of Collaboration Partners' Gross Profit Statement of changes in equity [line items] Statement of changes in equity [line items] Deviation due to local tax basis Tax Effect Of Deviation Due To Local Tax Basis Tax Effect Of Deviation Due To Local Tax Basis Current assets Current assets [abstract] Expense for proprietary antigen technology Research, Development And Commercialization Collaboration Agreement, Expense Research, Development And Commercialization Collaboration Agreement, Expense Summary of Inventories Disclosure Of Classes Of Inventories Explanatory [Table Text Block] Disclosure Of Classes Of Inventories Explanatory Percentage of exercise price increase Percentage Of Increase In Exercise Price Percentage Of Increase In Exercise Price Other financial assets Other financial assets in U.S. dollar Other Financial Assets [Member] Other Financial Assets Expected to be allocated as of estimated allocation date 2024, share options (in shares) Number Of Share Options Expected To Be Allocated In Share-Based Payment Arrangement, Year Three Number Of Share Options Expected To Be Allocated In Share-Based Payment Arrangement, Year Three Non-current Non-current lease liabilities Other (incl. deferred expenses) Other Deferred Taxes [Member] Other Deferred Taxes Trade Payables Trade Payables [Member] Trade Payables Investments in equity instruments designated at fair value through other comprehensive income [member] Investments in equity instruments designated at fair value through other comprehensive income [member] Forfeited (in euros per share) Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement General and administrative expenses General And Administrative Expenses [Member] General And Administrative Expenses Summary of Information about Parent Company Disclosure Of Significant Investments By Parent Company Explanatory [Table Text Block] Disclosure Of Significant Investments By Parent Company Explanatory Cash And Cash Equivalents [Line Items] Cash And Cash Equivalents [Line Items] Cash And Cash Equivalents [Line Items] BioNTech Cell & Gene Therapies GmbH BioNTech Cell And Gene Therapies GmbH [Member] BioNTech Cell And Gene Therapies GmbH Acquisition of non-controlling interest Increase (Decrease) Through Acquisition Of Noncontrolling Interests Increase (Decrease) Through Acquisition Of Noncontrolling Interests Inventories Total Current inventories Schedule of Expense Recognized for Employee Services Received Explanation of effect of share-based payments on entity's profit or loss [text block] Grant of options, base value Expected dividend, share options granted Expected tax credit / (benefit) Tax expense (income) at applicable tax rate Other reserves Other reserves Capital increase initial public offering (referred to as IPO) Increase (Decrease) Through Initial Public Offering Increase (Decrease) Through Initial Public Offering Change in deferred taxes due to tax rate change Tax effect from change in tax rate Undiscounted potential future lease payments related to renewal options not included in lease liabilities until 2049 Undiscounted Future Lease Payments Related To Renewal Options Not Included In Lease Liabilities Undiscounted Future Lease Payments Related To Renewal Options Not Included In Lease Liabilities Convertible note – host contract Convertible Note, Host Contract [Member] Convertible Note, Host Contract Financing activities Cash flows from (used in) financing activities [abstract] Investment into equity instruments designated at fair value through OCI Purchase Of Equity Investments Designate At Fair Value Through Other Comprehensive Income Purchase Of Equity Investments Designate At Fair Value Through Other Comprehensive Income Income and Expenses Disclosure Of Income And Expense Explanatory [Text Block] Disclosure Of Income And Expense Explanatory Recognized in P&L Deferred tax expense (income) recognised in profit or loss Adjustment prior year taxes Adjustments for current tax of prior periods Foreign exchange forward contracts Derivative financial liabilities Other comprehensive income / (loss) for the period, net of tax Other comprehensive income Summary of Other Assets Disclosure Of Detailed Information About Other Assets Explanatory [Table Text Block] Disclosure Of Detailed Information About Other Assets Explanatory Balance as of December 31, 2021 (in shares) Number of other equity instruments outstanding in share-based payment arrangement Revenue since acquisition date Revenue of acquiree since acquisition date Current Current lease liabilities Disclosure of quantitative information about right-of-use assets [table] Disclosure of quantitative information about right-of-use assets [table] Share options outstanding (in shares) Beginning balance, share options (in shares) Ending balance, share options (in shares) Number of share options outstanding in share-based payment arrangement Dr. Sierk Poetting Doctor Sierk Poetting [Member] Doctor Sierk Poetting Interest rate types [member] Interest rate types [member] State income tax with average rate Effective tax rate Average effective tax rate Disclosure of performance obligations [table] Disclosure of performance obligations [table] Purchases of property and other assets from entities controlled by ATHOS KG Purchases of property and other assets, related party transactions Weighted-average exercise price (in euros per share) Beginning balance, weighted-average exercise price (in euros per share) Ending balance, weighted-average exercise price (in euros per share) Weighted average exercise price of share options outstanding in share-based payment arrangement Outstanding balances Amounts payable, related party transactions Purchase of property, plant and equipment Purchase of property, plant and equipment, classified as investing activities BioNTech 2020 Employee Equity Plan for employees based outside North America BioNTech Employee Equity Plan For Employees Based In Europe [Member] BioNTech Employee Equity Plan For Employees Based In Europe Par value per share (in euros per share) Par value per share Financial liabilities Financial liabilities Within one year Less than 1 year Not later than one year [member] Total assets Assets Entity's total for related parties [member] Entity's total for related parties [member] Basic profit/(loss) for the period per share (in euros per share) Basic earnings (loss) per share ATHOS KG ATHOSKG [Member] ATHOSKG Disclosure Of Effect Of Changes In Foreign Exchange Rates [Table] Disclosure Of Effect Of Changes In Foreign Exchange Rates [Table] Disclosure Of Effect Of Changes In Foreign Exchange Rates [Table] Foreign exchange forward contracts Forward contract [member] Cumulative depreciation and impairment charges Accumulated depreciation, amortisation and impairment [member] Intellectual property rights Intellectual Property Rights [Member] Intellectual Property Rights Sales and Marketing Expenses Disclosure Of Sales And Marketing Expenses Explanatory [Table Text Block] Disclosure Of Sales And Marketing Expenses Explanatory Operating income / (loss) Profit (loss) from operating activities Hedging instruments [axis] Hedging instruments [axis] Net other comprehensive income / (loss) that will not be reclassified to profit or loss in subsequent periods Other comprehensive income that will not be reclassified to profit or loss, net of tax Research and development expenses Research and development expenses Research and development expense BioNTech Innovative Manufacturing Services GmbH BioNTech Innovative Manufacturing Services GmbH [Member] BioNTech Innovative Manufacturing Services GmbH Effects from tax losses Tax effect of tax losses Summary of Inputs Used in Measurement of Fair Value at Grant Date Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block] Accounting Policies, Changes In Accounting Estimates And Errors [Abstract] Accounting Policies, Changes In Accounting Estimates And Errors [Abstract] Accounting Policies, Changes In Accounting Estimates And Errors [Abstract] Other Liabilities [Abstract] Other Liabilities [Abstract] Expected to be allocated as of estimated allocation date 2025, weighted-average exercise price (in euros per share) Weighted Average Exercise Price Of Share Options Expected To Be Allocated In Share-Based Payment Arrangement, Year Four Weighted Average Exercise Price Of Share Options Expected To Be Allocated In Share-Based Payment Arrangement, Year Four Share-based payments Increase (decrease) through share-based payment transactions, equity BioNTech Innovation and Services Marburg GmbH (previously BioNTech Services Marburg GmbH) BioNTech Services Marburg GmbH [Member] BioNTech Services Marburg GmbH Number of entities acquired Number Of Entities Acquired Number Of Entities Acquired Statement of financial position [abstract] Deferred Interest At Fixed Rate Deferred Interest At Fixed Rate [Member] Deferred Interest At Fixed Rate Non-adjusting events after reporting period [member] Non-adjusting events after reporting period [member] Licenses Licences [member] Other financial liabilities Other Financial Liabilities Other Than Interest Bearing Loans And Borrowings [Member] Other Financial Liabilities Other Than Interest Bearing Loans And Borrowings Expected to be allocated as of estimated allocation date 2022, weighted-average exercise price (in euros per share) Weighted Average Exercise Price Of Share Options Expected To Be Allocated In Share-Based Payment Arrangement, Year One Weighted Average Exercise Price Of Share Options Expected To Be Allocated In Share-Based Payment Arrangement, Year One Wages, benefits and social security expense Wages, Benefits And Social Security Expense [Member] Wages, Benefits And Social Security Expense Cash deposit with an original term of six months Cash Deposit With Original Term Of Six Months [Member] Cash Deposit With Original Term Of Six Months Classes of financial assets [axis] Classes of financial assets [axis] Land and buildings Land and buildings [member] BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. [Member] BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. InstaDeep Ltd InstaDeep Ltd [Member] InstaDeep Ltd Issued Capital and Reserves Disclosure of share capital, reserves and other equity interest [text block] Schedule of Number and Weighted-Average Exercise Price of Share Options Disclosure of number and weighted average exercise prices of share options [text block] Inventory write-offs Inventory write-down Assets Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [abstract] Proposed dividends per share (in euros per share) Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners per share American Depositary Shares, each Representing one ordinary share American Depositary Shares Each Representing One Ordinary Share [Member] American Depositary Shares Each Representing One Ordinary Share Transaction costs Equity transaction costs Share issue related cost Share-based Payment Arrangements [Abstract] Share-based Payment Arrangements [Abstract] Share-based Payment Arrangements [Abstract] Right-of-use assets Right-of-use assets Total non-current Non-current government grants Non-current legal proceedings provision Non-current legal proceedings provision Events After Reporting Period [Abstract] Events After Reporting Period [Abstract] Consideration transferred Identifiable Assets Acquired, Liabilities Assumed And Goodwill Net Of Bargain Purchase Identifiable Assets Acquired, Liabilities Assumed And Goodwill Net Of Bargain Purchase Term loan (Credit B) Term Loan Credit B Term Loan Credit B Term loan (Credit A) Term Loan Credit A Term Loan Credit A Finance Expense Disclosure Of Finance Cost Explanatory [Table Text Block] Disclosure Of Finance Cost Explanatory Capital reserve Capital reserve Audit Information [Abstract] Audit Information As of January 1 As of December 31 Government grants Income taxes Income taxes Income taxes Tax expense (income) BioNTech Real Estate Haus Vier GmbH & Co. KG BioNTech Real Estate Haus Vier GmbH & Co. KG [Member] BioNTech Real Estate Haus Vier GmbH & Co. KG Aggregated time bands [member] Aggregated time bands [member] Disclosure of reconciliation of liabilities arising from financing activities [table] Disclosure of reconciliation of liabilities arising from financing activities [table] Entity Emerging Growth Company Entity Emerging Growth Company Remaining upfront fees contract liabilities Remaining Upfront Fees Contract Liabilities Remaining Upfront Fees Contract Liabilities Disclosure of transactions between related parties [line items] Disclosure of transactions between related parties [line items] Revenue of acquiree if combination occurred at beginning of period Revenue of combined entity as if combination occurred at beginning of period Other financial assets Other non-current financial assets Foreign exchange differences, net Net foreign exchange loss Non-current liabilities Non-current liabilities [abstract] Summary of Disaggregation of Revenues from Contracts with Customers Disclosure of disaggregation of revenue from contracts with customers [text block] Government grants Total current Current government grants Auditor Name Auditor Name Cover [Abstract] Investing activities Cash flows from (used in) investing activities [abstract] Current liabilities Current liabilities [abstract] Revenues Revenue [abstract] BMBF Government Grant BMBF Government Grant [Member] BMBF Government Grant Other assets Total non-current Other non-current assets Classes of intangible assets and goodwill [axis] Classes of intangible assets and goodwill [axis] Other operating expenses Other operating expenses Miscellaneous other operating expense Insurance premiums Insurance Premiums [Member] Insurance Premiums Disclosure of financial assets [line items] Disclosure of financial assets [line items] Decrease / (Increase) in trade and other receivables, contract assets and other assets Adjustments For Decrease (Increase) In Trade Accounts Receivable, Contract Assets And Other Assets Adjustments For Decrease (Increase) In Trade Accounts Receivable, Contract Assets And Other Assets Entity's total for subsidiaries [member] Entity's total for subsidiaries [member] Deferred tax assets Deferred tax assets BioNTech BioNTech [Member] BioNTech Prof. Özlem Türeci, M.D. Doctor Ozlem Tureci MD [Member] Doctor Ozlem Tureci MD Leases Disclosure of leases [text block] Deviation due to deviating income tax rate (Germany and foreign countries) Tax effect of foreign tax rates Research & development revenues Research And Development [Member] Research And Development Purchases of various goods and services from TRON Purchases of various goods and services from entities controlled by ATHOS KG Purchases Of Goods And Service Related Party Transactions Purchases Of Goods And Service Related Party Transactions Other Other Liabilities, Other Other Liabilities, Other Summary of Changes in Liabilities Arising from Financing Activities Disclosure of reconciliation of liabilities arising from financing activities [text block] Foreign exchange forward contracts Derivatives [member] Transaction costs Transaction costs of the acquisition (included in cash flows from operating activities) Acquisition-related costs recognised as expense for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination Estimated allocation date 2026 Estimated Allocation Date Five [Member] Estimated Allocation Date Five Expected to be allocated as of estimated allocation date 2026, share options (in shares) Number Of Share Options Expected To Be Allocated In Share-Based Payment Arrangement, Year Five Number Of Share Options Expected To Be Allocated In Share-Based Payment Arrangement, Year Five Repayment of loans and borrowings Repayments of borrowings, classified as financing activities Finance expense Adjustments for finance costs Total amounts recognized in profit or loss Lease Expenses Recognized In Profit Or Loss Lease Expenses Recognized In Profit Or Loss Prepayments on inventories Current prepaid expenses Right-of-use assets Right-Of-Use Assets Recognised As Of Acquisition Date Right-Of-Use Assets Recognised As Of Acquisition Date Disclosure of detailed information about business combination [table] Disclosure of detailed information about business combination [table] Cash and cash equivalents Cash and cash equivalents at the beginning of the period Cash and cash equivalents at December 31 Cash and cash equivalents at banks and on hand Cash and cash equivalents Provisions Non-current provisions Percentage of non-vesting rate Percentage Of Other Equity Instrument Non-Vesting Rate Percentage Of Other Equity Instrument Non-Vesting Rate Unfinished goods Current work in progress Retained earnings / (accumulated losses) Retained earnings Revenue From Contracts With Customers [Abstract] Revenue From Contracts With Customers [Abstract] Revenue From Contracts With Customers [Abstract] Net loss on derivative instruments at fair value through profit or loss Gains (losses) on financial liabilities at fair value through profit or loss Expected life (years) Option life, share options granted Consideration transferred Consideration transferred, acquisition-date fair value Property, plant and equipment Property, plant and equipment, beginning balance Property, plant and equipment, ending balance Property, plant and equipment Inventories Inventory recognised as of acquisition date Effect on pre-tax equity Foreign Currency Changes Effect On Pretax Equity Foreign Currency Changes Effect On Pretax Equity Management Board Grant Management Board Grant [Member] Management Board Grant Weighted average number of ordinary shares adjusted for the effect of dilution (in shares) Weighted average number of ordinary shares used in calculating diluted earnings per share Intangible Assets Disclosure of intangible assets [text block] Exercise price (in euros per share) Exercise price, share options granted Reclassifications Increase (decrease) through transfers and other changes, intangible assets and goodwill BioNTech Austria BioNTech Austria [Member] BioNTech Austria Deferred transportation cost Deferred Transportation Costs Deferred Transportation Costs Net cash flows from / (used in) financing activities Cash flows from (used in) financing activities Option rights vesting period Option Vesting Period Option Vesting Period Effects Reconciliation of accounting profit multiplied by applicable tax rates [abstract] Total financial liabilities at fair value Financial liabilities, at fair value Entity Address, City or Town Entity Address, City or Town Summary of Accumulated Tax Losses Disclosure Of Accumulated Tax Losses Explanatory [Table Text Block] Disclosure Of Accumulated Tax Losses Explanatory Ordinary shares Ordinary shares [member] Chief Executive Officer Grant Chief Executive Officer Grant [Member] Chief Executive Officer Grant 2.2% €10,000,000 secured bank loan Two Point One Five Percentage Secured Bank Loan [Member] Two Point One Five Percentage Secured Bank Loan Loans and borrowings Current borrowings Series B Series B [Member] Series B Share capital Issued capital [member] Income tax assets Current tax assets, current Temporary difference, unused tax losses and unused tax credits [member] Temporary difference, unused tax losses and unused tax credits [member] Profit / (loss) for the period Profit / (loss) for the period Profit (loss) Direct product sales to customers COVID-19 Vaccine, Direct Product Sales To Customers [Member] COVID-19 Vaccine, Direct Product Sales To Customers Convertible note coupon rate Financial Liabilities Coupon Rate Per Annum Financial Liabilities Coupon Rate Per Annum Entity Filer Category Entity Filer Category Summary of Contract Balances Disclosure Of Contract Balances From Contracts With Customers Explanatory [Table Text Block] Disclosure Of Contract Balances From Contracts With Customers Explanatory Balance as of December 31, 2021 (in euros per share) Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement Other Operating Expenses Disclosure Of Other Operating Expenses Explanatory [Table Text Block] Disclosure Of Other Operating Expenses Explanatory Supervisory Board Supervisory Board [Member] Supervisory Board Milestone payment recognized as revenue Milestone Payment Recognized As Revenue Milestone Payment Recognized As Revenue Consulting services / patent assignment Consulting Services And Patent Assignment Consulting Services And Patent Assignment Inventories [Abstract] Inventories [Abstract] Inventories [Abstract] Liabilities to employees Liabilities For Employee Benefits Liabilities For Employee Benefits Advance payment received for future COVID 19 vaccine sale Advance Payment Received For Future COVID-19 Vaccine Sale Advance Payment Received For Future COVID-19 Vaccine Sale LTI Program Employee Equity Plan, Long-Term Incentive Program [Member] Employee Equity Plan, Long-Term Incentive Program Tax-effective equity transaction costs Tax Effective Equity Transaction Costs Tax Effective Equity Transaction Costs Business combinations [axis] Business combinations [axis] Number of ordinary shares issuable (in shares) Number Of Ordinary Shares Issuable Number Of Ordinary Shares Issuable Cost of Sales Disclosure Of Costs Of Sales Explanatory [Table Text Block] Disclosure Of Costs Of Sales Explanatory Summary of Right-of-Use Assets within Consolidated Statements of Financial Position Disclosure of quantitative information about right-of-use assets [text block] Estimated allocation date 2024 Estimated Allocation Date Three [Member] Estimated Allocation Date Three Share-based payment arrangements [member] Share-based payment arrangements [member] Forfeited, number of ordinary shares underlying options (in shares) Number Of Ordinary Shares Underlying Options Forfeited In Share-based Payment Arrangement Number Of Ordinary Shares Underlying Options Forfeited In Share-based Payment Arrangement Amendment Flag Amendment Flag BioNTech Manufacturing Marburg GmbH BioNTech Manufacturing Marburg GmbH [Member] BioNTech Manufacturing Marburg GmbH Disclosure Of Income And Expenses [Line Items] Disclosure Of Income And Expenses [Line Items] Disclosure Of Income And Expenses 2.1% €9,450,000 secured bank loan Two Point Zero Eight Percentage Secured Bank Loan [Member] Two Point Zero Eight Percentage Secured Bank Loan Granted, weighted-average exercise price (in euros per share) Weighted average exercise price of share options granted in share-based payment arrangement Total depreciation charge Depreciation, right-of-use assets Other comprehensive loss that will not be reclassified to profit or loss in subsequent periods, net of tax Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract] Non-adjusting events after reporting period [axis] Non-adjusting events after reporting period [axis] BioNTech Turkey Tıbbi Ürünler Ve Klinik Araştirma Ticaret Anonim Şirketi BIONTECH TURKEY TIBBİ ÜRÜNLER VE KLİNİK ARAŞTIRMA TİCARET ANONİM ŞİRKETİ [Member] BIONTECH TURKEY TIBBİ ÜRÜNLER VE KLİNİK ARAŞTIRMA TİCARET ANONİM ŞİRKETİ Current income taxes Current tax expense (income) Product and Service [Axis] Product and Service [Axis] Non-controlling interests Comprehensive income, attributable to non-controlling interests Shares issued (in shares) Number of shares issued Corporate Information Disclosure Of Corporate Information Explanatory [Text Block] Disclosure Of Corporate Information Explanatory Significant Accounting Judgments, Estimates and Assumptions Disclosure of accounting judgements and estimates [text block] Income And Expenses By Nature [Domain] Income And Expenses By Nature [Domain] Income And Expenses By Nature [Domain] Cash dividend for 2021: €2.00 per share Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners Finished goods Current finished goods Interest received Interest received, classified as operating activities Movements in government grants Adjustments For Movements In Government Grants Adjustments For Movements In Government Grants Expected to be allocated as of estimated allocation date 2022, share options (in shares) Number Of Share Options Expected To Be Allocated In Share-Based Payment Arrangement, Year One Number Of Share Options Expected To Be Allocated In Share-Based Payment Arrangement, Year One Recognized in OCI Deferred Tax Expense (Income) Recognised In Other Comprehensive Income Deferred Tax Expense (Income) Recognised In Other Comprehensive Income Automobiles Vehicles [member] Changes in fair value Increase (decrease) through changes in fair values, liabilities arising from financing activities Disclosure of reconciliation of changes in intangible assets and goodwill [table] Disclosure of reconciliation of changes in intangible assets and goodwill [table] Total non-current liabilities Non-current liabilities Summary of Transactions Between Other Related Parties Disclosure of transactions between related parties [text block] Total Goods And Services From Related Party Transactions Goods And Services From Related Party Transactions Upfront payment Collaboration Agreement, Upfront Payment Collaboration Agreement, Upfront Payment Fair Value Measurement Description of accounting policy for fair value measurement [text block] Performance obligations [member] Performance obligations [member] Financial liabilities in U.S. dollar Financial Liability [Member] Financial Liability Estimated allocation date 2025 Estimated Allocation Date Four [Member] Estimated Allocation Date Four Other comprehensive income / (loss) Other comprehensive income [abstract] Document Annual Report Document Annual Report Forecast Forecast [Member] Estimated allocation date 2022 Estimated Allocation Date One [Member] Estimated Allocation Date One Other Operating Income Disclosure Of Other Operating Income Explanatory [Table Text Block] Disclosure Of Other Operating Income Explanatory ADS share price, maximum percentage of cash payment Key Management Personnel Compensation, American Depository Share Price, Maximum Percentage Of Cash Payment Key Management Personnel Compensation, American Depository Share Price, Maximum Percentage Of Cash Payment Geographical [Domain] Geographical [Domain] Equipment, tools and installations Equipment, Tools And Installations [Member] Equipment, Tools And Installations Federal tax losses Federal Deferred Tax Assets Operating Loss Carryforwards Federal Deferred Tax Assets Operating Loss Carryforwards Jens Holstein Jens Holstein [Member] Jens Holstein Pfizer Inc. Pfizer Inc [Member] Pfizer Inc Forfeited (in shares) Number of other equity instruments forfeited in share-based payment arrangement Financial Instruments [Abstract] Financial Instruments [Abstract] Financial Instruments [Abstract] Earnings per share [table] Earnings per share [table] Classes of share capital [axis] Classes of share capital [axis] Summary of Lease Liability Included in Interest-Bearing Loans and Borrowings Disclosure Of Detailed Information About Lease Liabilities Explanatory [Table Text Block] Disclosure Of Detailed Information About Lease Liabilities Explanatory Fair value adjustments of financial instruments measured at fair value Fair value adjustment derived from remeasuring embedded derivative Fair Value Adjustments Of Financial Instruments Measured At Fair Value Fair Value Adjustments Of Financial Instruments Measured At Fair Value All Currencies [Domain] All Currencies [Domain] Provisions and Contingencies Disclosure of provisions [text block] Other Assets [Abstract] Other Assets Remaining capacity Value Of Shares Remaining For Issuance Of Ordinary Shares Value Of Shares Remaining For Issuance Of Ordinary Shares Segment Information Description of accounting policy for segment reporting [text block] Trade and other receivables Trade And Other Receivables [Member] Trade And Other Receivables Shares issued, at fair value Shares Issued At Fair Value Shares Issued At Fair Value Business Combinations Disclosure of business combinations [text block] JPT Peptide Technologies GmbH JPT Peptide Technologies GmbH [Member] JPT Peptide Technologies GmbH Ranges [member] Ranges [member] Financial assets at fair value through profit or loss Financial assets at fair value through profit or loss, category [member] Equity Equity [abstract] Contact Personnel Fax Number Contact Personnel Fax Number Other assets Total current Other current assets Summary of Current and Deferred Tax Expense Disclosure Of Current And Deferred Tax Expense Explanatory [Table Text Block] Disclosure Of Current And Deferred Tax Expense Explanatory Analysis of income and expense [abstract] Finance Income Disclosure Of Finance Income Explanatory [Table Text Block] Disclosure Of Finance Income Explanatory New leases and disposals Increase through new leases, liabilities arising from financing activities Financial assets, category [member] Financial assets, category [member] Income And Expenses By Nature [Axis] Income And Expenses By Nature [Axis] Income And Expenses By Nature Performance obligations [axis] Performance obligations [axis] Total Deferred Expense Deferred Expense Schedule of Standards Applied for the First Time Disclosure of initial application of standards or interpretations [text block] Total assets Assets Recognised As Of Acquisition Date Assets Recognised As Of Acquisition Date Right-of-use assets, Useful life (Years) Useful Life Measured As Period Of Time, Right-Of-Use Assets Useful Life Measured As Period Of Time, Right-Of-Use Assets BioNTech Restricted Stock Unit Plan for North America Employees BioNTech 2020 Restricted Stock Unit Plan For North America Employees BioNTech 2020 Restricted Stock Unit Plan For North America Employees [Member] BioNTech 2020 Restricted Stock Unit Plan For North America Employees Non-tax effective bargain purchase Non Tax Effective Bargain Purchase Non Tax Effective Bargain Purchase BioNTech US Inc. BioNTech US Inc. [Member] BioNTech US Inc. Comprehensive income / (loss) for the period, net of tax Comprehensive income Standards Applied for the First Time Disclosure Of Accounting Policy For Initial Application Of Standards Or Interpretations Explanatory [Policy Text Block] Disclosure Of Accounting Policy For Initial Application Of Standards Or Interpretations Explanatory Income from derivative instruments at fair value through profit and loss Earnings On Derivative Instruments At Fair Value Through Profit Or Loss [Member] Earnings On Derivative Instruments At Fair Value Through Profit Or Loss Remuneration payment, period of recognition Remuneration Payment, Period Of Recognition Remuneration Payment, Period Of Recognition BioNTech Delivery Technologies GmbH BioNTech Delivery Techonologies GmbH [Member] BioNTech Delivery Techonologies GmbH Foreign Currencies Description of accounting policy for foreign currency translation [text block] Capital requirements [axis] Capital requirements [axis] Expense relating to leases of low-value assets that are not short-term leases (included in other expenses) Expense relating to leases of low-value assets for which recognition exemption has been used Total revenues Revenue from contracts with customers General and administrative expenses General and administrative expenses General and administrative expense Entity Central Index Key Entity Central Index Key Other financial liabilities Other financial liabilities Percentage of shares acquired in equity instruments Percentage Of Shares Acquired Of Investment In Equity Instrument Designated At Fair Value Through Other Comprehensive Income Percentage Of Shares Acquired Of Investment In Equity Instrument Designated At Fair Value Through Other Comprehensive Income Total liabilities Liabilities Recognised As Of Acquisition Date Liabilities Recognised As Of Acquisition Date Vesting [Domain] Vesting [Domain] Vesting [Domain] Types of interest rates [axis] Types of interest rates [axis] 1 to 5 years Later than two years and not later than five years [member] Share Capital, Reserves and Other Equity Interest [Abstract] Share Capital, Reserves and Other Equity Interest [Abstract] Share Capital, Reserves and Other Equity Interest [Abstract] Bad debt expense has been recognized Expense recognised during period for bad and doubtful debts for related party transaction Disclosure of terms and conditions of share-based payment arrangement [table] Disclosure of terms and conditions of share-based payment arrangement [table] Interest income Interest income Expense arising from equity-settled share-based payment arrangements Expense from equity-settled share-based payment transactions Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items] Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items] Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items] Consideration Acquisition-date fair value of total consideration transferred [abstract] Capital reserve Capital reserve [member] Trading Symbol Trading Symbol Useful Lives Applied to the Group's Right-of-use Assets Disclosure Of Right-Of-Use Assets Estimated Useful Lives Explanatory [Table Text Block] Disclosure Of Right-Of-Use Assets Estimated Useful Lives Explanatory Related Party Disclosures Disclosure of related party [text block] Current provisions for inventor remuneration Current Provisions For Inventor Remuneration Current Provisions For Inventor Remuneration Intangible assets Beginning balance Ending balance Intangible assets and goodwill Outstanding balances of related party transactions Provisions for doubtful debts related to outstanding balances of related party transaction Notional amount Notional amount Deferred expenses Total non-current Deferred Expense, Non-Current Deferred Expense, Non-Current Summary of Carrying Amount of Monetary Assets Disclosure Of Foreign Currency Risk Explanatory [Table Text Block] Disclosure Of Foreign Currency Risk Explanatory Share-based payment expense Adjustments for share-based payments Investment in convertible note Investments accounted for using equity method Employee Stock Ownership Plan Employee Stock Ownership Plan [Member] Employee Stock Ownership Plan Interests In Other Entities [Abstract] Interests In Other Entities [Abstract] Interests In Other Entities [Abstract] Finance income Finance income Finance income EIB Manufacturing Financing European Investment Bank [Member] European Investment Bank Net increase / (decrease) in cash and cash equivalents Increase (decrease) in cash and cash equivalents before effect of exchange rate changes Related Party [Abstract] Related Party [Abstract] Related Party [Abstract] Funding received Received during the year Government Grants Received Government Grants Received Statement of cash flows [abstract] Total Cash And Cash Equivalent Cash And Cash Equivalent Summary of Effect of Changes in Foreign Exchange Rates Disclosure Of Effect Of Changes In Foreign Exchange Rates Explanatory [Table Text Block] Disclosure Of Effect Of Changes In Foreign Exchange Rates Explanatory Carrying amount [member] Carrying amount [member] Disclosure of subsidiaries [line items] Disclosure of subsidiaries [line items] BioNTech UK Limited BioNTech UK Limited [Member] BioNTech UK Limited Acquisition of subsidiaries and businesses Acquisitions through business combinations, intangible assets and goodwill Categories of related parties [axis] Categories of related parties [axis] Gain on disposal of property, plant and equipment Adjustments for gain (loss) on disposals, property, plant and equipment Conversion premium of convertible note Financial Liabilities, Conversion Premium, Percentage Above Reference Price Financial Liabilities, Conversion Premium, Percentage Above Reference Price Weighted average number of ordinary shares for basic EPS (in shares) Weighted average number of ordinary shares used in calculating basic earnings per share Temporary difference, unused tax losses and unused tax credits [axis] Temporary difference, unused tax losses and unused tax credits [axis] Total Purchases From Related Party Transactions Purchases From Related Party Transactions Convertible note – embedded derivative Convertible Note, Embedded Derivative [Member] Convertible Note, Embedded Derivative Auditor Firm ID Auditor Firm ID Intangible Assets Description of accounting policy for intangible assets and goodwill [text block] Deferred expenses from insurance contracts Deferred Expenses From Insurance Contracts Deferred Expenses From Insurance Contracts Software Computer software [member] Total identifiable net assets at fair value Identifiable assets acquired (liabilities assumed) Disclosure of temporary difference, unused tax losses and unused tax credits [line items] Disclosure of temporary difference, unused tax losses and unused tax credits [line items] Cost of sales Cost of sales Cost of sales Components of equity [axis] Components of equity [axis] Ownership [Domain] Ownership [Domain] Taxes Description of accounting policy for income tax [text block] Financial assets at amortised cost Financial assets at amortised cost, category [member] Current versus Non-Current Classifications Description Of Accounting Policy For Assets And Liabilities Explanatory [Policy Text Block] Description Of Accounting Policy For Assets And Liabilities Explanatory Disclosure of non-adjusting events after reporting period [table] Disclosure of non-adjusting events after reporting period [table] Amortization Accumulated Depreciation, Amortisation And Impairment Accumulated Depreciation, Amortisation And Impairment Maximum value of phantom shares Key Management Personnel Compensation, Maximum Value Of Phantom Shares Key Management Personnel Compensation, Maximum Value Of Phantom Shares Laboratory supplies Laboratory Supplies [Member] Laboratory Supplies Attributable to: Comprehensive income attributable to [abstract] Disclosure of reconciliation of liabilities arising from financing activities [line items] Disclosure of reconciliation of liabilities arising from financing activities [line items] Issuance of share capital Issuance Of Share Capital Issuance Of Share Capital Types of share-based payment arrangements [axis] Types of share-based payment arrangements [axis] Summary of Information about Subsidiaries Disclosure of subsidiaries [text block] BioNTech Real Estate an der Goldgrube 12 GmbH & Co. KG BioNTech Real Estate an der Goldgrube 12 GmbH & Co. KG [Member] BioNTech Real Estate an der Goldgrube 12 GmbH & Co. KG Income Taxes [Abstract] Income Taxes [Abstract] Income Taxes [Abstract] Ryan Richardson Ryan Richardson [Member] Ryan Richardson Cash flows Increase (decrease) through financing cash flows, liabilities arising from financing activities Income tax liabilities Current tax liabilities, non-current Intangible assets other than goodwill [member] Intangible assets other than goodwill [member] Other financial assets Other current financial assets Disposals Disposals, property, plant and equipment Effect on profit / (loss) before tax Foreign Currency Changes Effect On Loss, Before Tax Foreign Currency Changes Effect On Loss, Before Tax Risks [member] Risks [member] Acquisition of subsidiaries and businesses, net of cash acquired Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities Interest expenses related to financial assets Interest Expense On Financial Assets Interest Expense On Financial Assets Share-based payment, ordinary shares (in shares) Key Management Personnel Compensation Share Based Payment Ordinary Shares Key Management Personnel Compensation Share Based Payment Ordinary Shares Trade payables Trade Payables Recognised As Of Acquisition Date Trade Payables Recognised As Of Acquisition Date Useful life measured as period of time, intangible assets other than goodwill Useful life measured as period of time, intangible assets other than goodwill